GTBP•GT Biopharma shareholders approved increasing authorized common shares from 25 million to 250 million and authorized common stock issuance upon conversion of Series M preferred stock and exercise of warrants.
At a special meeting on November 11, 2026, shareholders approved increasing authorized common shares from 25 million to 250 million and authorized common stock issuance upon conversion of Series M 10% Convertible Preferred Stock and exercise of Warrants. They also approved a charter amendment eliminating references to obsolete preferred stock series; both charter amendments were authorized for implementation by November 11, 2027. Shareholders approved adjournment if needed to establish a quorum or solicit additional proxies.
